The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use, Clinical Cancer Research, vol.17, issue.21, pp.6608-6614, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-1734
Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients, Cancer Chemotherapy and Pharmacology, vol.39, issue.1-2, pp.131-137, 1996. ,
DOI : 10.1007/s002800050548
Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry, Biochemical Medicine, vol.18, issue.2, pp.184-191, 1977. ,
DOI : 10.1016/0006-2944(77)90089-8
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients, British Journal of Clinical Pharmacology, vol.38, issue.6, pp.756-763, 2004. ,
DOI : 10.1046/j.1365-2125.1996.04231.x
Pharmacokinetics of pazopanib administered in combination with bevacizumab, Cancer Chemotherapy and Pharmacology, vol.37, issue.Suppl 1, pp.1189-1196, 2014. ,
DOI : 10.1016/j.ctrv.2010.08.006
Phase I Trial of Pazopanib in Patients with Advanced Cancer, Clinical Cancer Research, vol.15, issue.12, pp.4220-4227, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2740
Cisplatin nephrotoxicity: diethyldithiocarbamate, WR2721, or just water?, Journal of Clinical Oncology, vol.9, issue.4, pp.707-709, 1991. ,
DOI : 10.1200/JCO.1991.9.4.707
A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT, Drug Metabolism and Disposition, vol.34, pp.495-503, 2006. ,
DOI : 10.1124/dmd.105.008458
URL : http://dmd.aspetjournals.org/content/dmd/34/3/495.full.pdf
Pazopanib, Drugs, vol.71, pp.443-454, 2011. ,
DOI : 10.2165/11588960-000000000-00000
Aprepitant: drug-drug interactions in perspective, Annals of Oncology, vol.11, issue.3, pp.2316-2323, 2010. ,
DOI : 10.1200/JCO.2006.06.9591
URL : https://academic.oup.com/annonc/article-pdf/21/12/2316/499758/mdq149.pdf
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients, Cancer Chemotherapy and Pharmacology, vol.56, issue.3, pp.407-412, 2007. ,
DOI : 10.1016/j.ejca.2003.08.028
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients, Cancer Chemotherapy and Pharmacology, vol.36, issue.6, pp.609-616, 2005. ,
DOI : 10.1007/s00280-004-0946-3
Aprepitant for Erlotinib-Induced Pruritus, New England Journal of Medicine, vol.363, issue.4, pp.397-398, 2010. ,
DOI : 10.1056/NEJMc1003937
Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity, The Journal of Clinical Pharmacology, vol.254, issue.3, pp.215-223, 2004. ,
DOI : 10.1006/bbrc.1998.9992
Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors, Molecular Cancer Therapeutics, vol.11, issue.8, pp.1820-1828, 2012. ,
DOI : 10.1158/1535-7163.MCT-11-0997
Cisplatin Pharmacokinetics Using a Five-Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors, Therapeutic Drug Monitoring, vol.17, issue.1, pp.25-32, 1995. ,
DOI : 10.1097/00007691-199502000-00005
Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin, Biochemical Pharmacology, vol.33, issue.19, pp.3063-3070, 1984. ,
DOI : 10.1016/0006-2952(84)90610-5
Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe, Clinical Pharmacology & Therapeutics, vol.74, issue.2, pp.150-156, 2003. ,
DOI : 10.1016/S0009-9236(03)00123-1
An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors, Clinical Pharmacology & Therapeutics, vol.48, issue.5, pp.652-659, 2010. ,
DOI : 10.1038/clpt.2010.158
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma, British Journal of Cancer, vol.8, issue.10, pp.1909-1916, 2014. ,
DOI : 10.1097/FTD.0b013e3181b2c8cf
URL : http://www.nature.com/bjc/journal/v111/n10/pdf/bjc2014503a.pdf